부산대학교 도서관

Metastatic prostate cancer is a hormone sensitive cancer. For patients with prostate cancer, general surgeons and urologists are the points of first contact. Historically, restricted treatment options meant that such patients were started on, and continued hormonal therapy with them. Chemotherapy is started once these tumours became hormone-refractory, with limited survival benefits. However, three recently published randomized, Phase III trials (GETUG-AFU15, CHAARTED, STAMPEDE) have provided Level I evidence that upfront chemotherapy in hormone sensitive metastatic prostate cancer dramatically improves survival, especially in those with heavy volume disease (an increase of up to 22 months). The authors recommend that general surgeons and urologists discuss patients in multi-disciplinary tumour boards so that fit patients can receive the benefits of upfront chemotherapy.
Author(s): Ajit Venniyoor [sup.1], Itrat Mehdi [sup.1], Rajan Balakrishnan [sup.2], Bassim Al Bahrani [sup.1] Author Affiliations: (1) grid.416132.3, 0000 0004 1772 5665, Medical Oncology, National Oncology Centre, The Royal Hospital, [...]